Objective. To determine the frequency, time to flare, and predictors of disease flare upon withdrawal of anti-tumor necrosis factor (anti-TNF) therapy in children with polyarticular forms of juvenile idiopathic arthritis (JIA) who demonstrated ≥6 months of continuous clinically inactive disease.
1, 2, 3, 4, 6, and 8 months. Life-table analysis, t-tests, chisquare test, and Cox regression analysis were used to identify independent variables that could significantly predict flare by 8 months or time to flare.
Results. Of 137 patients, 106 (77%) maintained clinically inactive disease while receiving anti-TNF therapy for the initial 6 months and were included in the phase of the study in which anti-TNF therapy was stopped. Stopping anti-TNF resulted in disease flare in 39 (37%) of 106 patients by 8 months. The mean/median AE SEM time to flare was 212/250 AE 9.77 days. Patients with shorter disease duration at enrollment, older age at onset and diagnosis, shorter disease duration prior to experiencing clinically inactive disease, and shorter time from onset of clinically inactive disease to enrollment were found to have significantly lower hazard ratios for likelihood of flare by 8 months (P < 0.05).
Conclusion. Over one-third of patients with polyarticular JIA with sustained clinically inactive disease will experience a flare by 8 months after discontinuation of anti-TNF therapy. Several predictors of lower likelihood of flare were identified.
Current treatment approaches for children with polyarticular forms of juvenile idiopathic arthritis (JIA) (1) have resulted in up to 50% of patients demonstrating clinically inactive disease (2) while receiving treatment (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . Much of the success in inducing clinically inactive disease is due to the introduction of anti-tumor necrosis factor (anti-TNF) biologic therapies used early in the treatment of a large proportion of children with JIA (4) (5) (6) (7) (8) (12) (13) (14) (15) . Anti-TNF therapy has shown short-and medium-term toxicities in children with JIA; the longterm toxicities (>15 years) are unknown, and the medication cost is substantial (5, 13, (16) (17) (18) (19) (20) (21) (22) (23) (24) . Prediction of which children with clinically inactive JIA receiving anti-TNF therapies can discontinue therapy without experiencing a recurrence of clinically active disease is presently limited to retrospective or small prospective cohort studies and studies of proposed biomarkers (25) (26) (27) (28) (29) . Studies describing which patients may safely discontinue treatment once clinically inactive disease is achieved have not been fully validated (30, 31) .
The objective of this study was to determine the time-based risk of disease flare in patients with polyarticular forms of JIA (rheumatoid factor [RF] positive or negative and extended oligoarticular JIA) who had experienced sustained clinically inactive disease at the time anti-TNF therapy was withdrawn. Secondary objectives included 1) the identification of clinical and demographic variables that impact time to flare and risk of flare, and 2) the impact of background methotrexate (MTX) on time to flare and risk of flare after withdrawal of anti-TNF therapy.
PATIENTS AND METHODS
Study design and patient flow. This multicenter, prospective study had 2 phases conducted over a 14-month, on-protocol period. In the first 6-month phase patients who were in a state of clinically inactive disease were enrolled and continued an anti-TNF agent and background drugs (if applicable). If clinically inactive disease was maintained for the initial 6 months of the study, the patient became eligible for the second phase, during which anti-TNF therapy was withdrawn while background medications were held stable. Anti-TNF withdrawal was done according to protocol at all sites, and in all instances anti-TNF therapy was discontinued completely at the month 6 study visit and not tapered. These "evaluable patients" returned for study visits at 1, 2, 3, 4, 6, and 8 months to determine if their disease had flared according to prespecified criteria (see below for definition). The protocol did not specify "study visit windows" outside of which data would be discarded. While >90% of visits occurred within 2 weeks of the expected study date, some were outside this span. These data were used in the analysis, resulting in the maximum follow-up after stopping the anti-TNF agent being up to 8 months in 67 patients and >8 but ≤10 months in 39 patients.
The study was approved by the Institutional Review Board (IRB) at each participating site and was conducted in compliance with the Declaration of Helsinki (https://www.wma. net/policies-post/wma-declaration-of-helsinki-ethical-principlesfor-medical-research-involving-human-subjects/). Parent/patient consent (and assent, if appropriate) was obtained, and patients were screened for eligibility at the participating site at which the patient was recruited. Each patient's eligibility was validated via eligibility case report forms immediately sent to the Pediatric Rheumatology Collaborative Study Group Coordinating Center at Cincinnati Children's Hospital Medical Center. The coordinating center served as the clinical research organization for this study and oversaw all matters related to regulatory, financial, and clinical affairs, as well as data management, quality assurance, and analysis.
An independent Data and Safety Monitoring Board (DSMB) appointed by the National Institutes of Health (NIH)/ National Institute of Arthritis and Musculoskeletal and Skin Diseases monitored all aspects of the study including recruitment and retention rate, modifications to the protocol, and/or changes to the case report forms, and any concerns regarding patients' overall well-being and safety. An initial DSMB meeting was held prior to study initiation to resolve outstanding issues. Following study startup, and for the first 2 years of enrollment, the DSMB met with all coordinating center personnel via teleconference every 3 months. The teleconferences were conducted using a standardized protocol for DSMB meetings. As the study progressed, teleconferences were less frequent unless problems arose. The only problem resulting in an ad hoc DSMB meeting was slow patient enrollment. The DSMB members played an active, collaborative role in addressing enrollment issues and successfully advocated for increased and extended funding for the study from the NIH.
Patients were recruited from tertiary pediatric rheumatology centers in the US beginning in July 2009. Prior to the start of patient recruitment, a face-to-face investigators' meeting was held with all original study sites in attendance. New sites were added as the study progressed to increase the rate of enrollment. Personnel at new sites underwent identical training to that presented at the investigators' meeting during an on-site visit by the study principal investigator (DJL).
Outcome measures. The primary outcome for this study was disease flare using a variation of the validated criteria defined as 30% worsening in 3 or more of any of the 6 JIA American College of Rheumatology (ACR) core set variables (32) , with no more than 1 improving by >30% (33). The 6 core set variables include the physician's global assessment of disease activity (on a visual analog scale [VAS] of 0-10, where 0 = inactive disease), parent/patient assessment of overall well-being (on a VAS of 0-10, where 0 = best well-being), functional ability measured by the Childhood Health Assessment Questionnaire (C-HAQ), the number of joints with active arthritis (using the ACR definition of active joint) (32) , the number of joints with limited range of motion, and an acute-phase reactant (erythrocyte sedimentation rate [ESR] was used in this study). Because enrolled subjects began the second phase with clinically inactive disease so that most of the core set variables were normal or 0, a 30% worsening could represent a less than clinically important change. Thus, in this study, to be considered to have experienced a flare on a particular parameter, the patient had to experience worsening by at least 30% and also demonstrate a minimum change in the following amounts: increase in physician's global assessment of disease activity or parent/patient assessment of overall well-being by at least 2 units on a 21-circle 0-10 unit VAS (34) , increase in the number of joints with active arthritis or number of joints with limited range of motion by at least 2, an increase of a minimum of +0.125 on the C-HAQ (validated minimum clinically important difference) (35) , and an increase in the ESR from normal to abnormal. Patients who demonstrated active uveitis were considered to have experienced a flare.
Clinically inactive disease was defined using the ACR provisional criteria (2) for clinically inactive disease in JIA and includes the following: no joints with active arthritis (using the ACR definition of active joint) (32) , no fever, rash, or serositis attributable to JIA, no active uveitis (as per the most recent examination by an ophthalmologist), an ESR less than or equal to the upper limit of the normal range for the assay used at the site (ESR could be elevated and the patient still be considered to have clinically inactive disease if the elevation was not attributable by the treating physician to JIA), physician's global assessment of disease activity of ≤0.5 on a 21-circle 0-10 unit VAS, and duration of morning stiffness of ≤15 minutes. "Clinical remission on medications" was also defined using the ACR provisional criteria and required disease to be clinically inactive for 6 continuous months.
Inclusion and exclusion criteria. To be eligible for enrollment into the initial 6-month phase, subjects had to be between 4 and 20 years of age with a diagnosis of polyarticular JIA (either RF positive or negative) or extended oligoarticular JIA (1) and have clinically inactive disease while receiving etanercept, adalimumab, or infliximab. All Food and Drug Administration label exclusions for anti-TNF therapy had to be absent, a history of regular slit-lamp examinations as recommended by the American Academy of Pediatrics guidelines (36) had to be present, and the hemoglobin concentration had to be ≥10 gm/dl at baseline. Females of childbearing potential and males who had reached puberty had to agree to use adequate contraception or practice abstinence during the study. An IRB-approved consent form (and assent if applicable) had to be signed. Exclusion criteria included diagnosis with other categories of JIA, previous treatment with rituximab, concurrent treatment with any other biologic agent, or corticosteroids >0.2 mg/kg/day or >10 mg/day (whichever was less). Patients with a diagnosis of any other inflammatory, acute, or chronic illness that might affect laboratory results or the inability to discontinue anti-TNF biologic therapy were excluded.
Allowable treatments. Anti-TNF therapies allowed during the first 6 months of the study included etanercept, infliximab, and adalimumab. The choice of which anti-TNF was used was at the discretion of the examining physician. Dosing and method of administration followed recommended guidelines. Patients were permitted to receive stable background therapy with nonsteroidal antiinflammatory drugs, MTX, other diseasemodifying antirheumatic drugs (DMARDs) (except rituximab), and low-dose corticosteroids (prednisone dose ≤0.2 mg/kg/day or ≤10 mg/day, whichever was less). All background therapies for JIA were to remain unchanged from the time of enrollment until the final study visit or discontinuation from the study. Data management, sample size, and statistical methods. Case report forms were sent from participating sites, via fax, to the study coordinating center where forms underwent real-time quality control procedures since all data required for the determination of "flare" had to be collected, verified, and analyzed before the end of the study visit before any treatment changes were made. Additional data requests were issued if necessary. All data were stored, managed, and analyzed using REDCap, Microsoft Excel, and SAS (version 9.3TS), respectively.
Sample size estimation accommodated the following possibilities: 1) background MTX therapy may affect the frequency of disease flare, 2) not all subjects enrolled in the study will exhibit persistent clinically inactive disease for the initial 6 months (and thus will not be included in the withdrawal phase), and 3) some patients will become lost to follow-up due to reasons beyond the control of the investigators. We anticipated that 102 evaluable patients would be necessary to test the hypothesis that 60% of the patients would experience a disease flare within 8 months of discontinuation of anti-TNF therapy, assuming that half of these patients would be receiving MTX. To attain enough evaluable patients, with an anticipated dropout/non-evaluable rate of 15%, we estimated that 118 patients would need to be enrolled to meet statistical power requirements of 80%. The sample size was calculated to address the specific aims of the grant, one of which included the diagnostic ability of biomarkers. The sample size was calculated using the method described by Obuchowski and McClish (37) .
Descriptive statistics were used to summarize medications and demographic and disease characteristics at baseline and 6 months. Kaplan-Meier survival curves were generated to estimate rate of flare over time following anti-TNF withdrawal for the study population and stratified by covariates, including type of anti-TNF agent used (adalimumab, etanercept, or infliximab), JIA category (extended oligoarticular, RF-positive polyarticular, RF-negative polyarticular), and background MTX use (yes/no). Likelihood ratios and chi-square statistics were used to compare the survivorship functions among groups. Multivariable logistic analysis was used to model risk of flare (yes/no). Cox regression analyses were used to assess predictors of time to flare. Hazard ratios (HRs) were calculated to identify potential independent predictors of flare by 8 months. Stepwise selection procedures were used where variables with P values less than 0.25 from univariable analysis were entered in the multivariable analysis, and only those significant at P < 0.05 were retained. Interaction terms that were clinically meaningful were also considered. The interactions we considered were: MTX by anti-TNF agent, JIA subtype by sex, and JIA subtype by age. The final model only retains the MTX by anti-TNF agent interaction.
Some variables, such as the age and time duration variables, are known to be collinear. Entering all these variables in the same regression equation would cause collinearity issues. We selectively entered variables and avoided those that were derived from an already entered variable. In addition, some nonderived variables may present strong correlations with other variables in the model. To address this issue, we used the ridge option in the logistic regression procedure (38) , which helps stabilize the regression estimate. For some § Data were not available for 2 patients. In order to be included in the analysis, these 2 patients were considered to be negative for rheumatoid factor (RF). ¶ Data were not available for 1 patient.
variables in the regression analysis, the model suffers from very small cell size. The Firth option was used in the analysis to address this issue (39) .
Biospecimens. Blood was obtained from each subject at baseline and at various follow-up visits for purposes of genetic, gene expression, and translational studies. The results of those studies are to be reported elsewhere.
RESULTS
Patient characteristics. Sixteen tertiary pediatric centers in the US enrolled a total of 137 patients who met the eligibility criteria. Review of the prescreening logs indicated that 137 (93.1%) of 147 eligible subjects screened were enrolled. Data were locked for this analysis in August 2014. Demographic and disease characteristics and pharmacologic treatments of the enrolled population are given in Table 1 . One subject received an additional nonbiologic DMARD (hydroxychloroquine), and 1 other subject received corticosteroids. Seven (5.1%) of the 137 subjects had been treated with another biologic drug in the 6 months prior to the baseline visit. Four (2.9%) of the 137 had a history of uveitis. Slit-lamp examinations, as per the American Academy of Pediatrics guidelines (36), were required before and during the study. Uveitis status was part of the definition of clinically inactive disease. Three (2.2%) of the 137 patients were no longer considered to have clinically inactive disease due to a flare of uveitis.
Patient disposition. Figure 1 provides a summary of the outcomes for all enrolled patients. Seven (5%) of the 137 enrolled patients dropped out during the first 6 months (6 due to being lost to follow-up or noncompliance and 1 due to a change in JIA category). Of the remaining 130, 24 (18.5%) did not remain in clinical remission while receiving medications, i.e., maintain clinically inactive disease for the first 6 months, despite stable anti-TNF and background medications. Thus, a total of 106 (77.4% of the total number enrolled) were considered evaluable and entered the second phase of the study.
Demographic, disease, and treatment characteristics of those unable to maintain clinically inactive disease for 6 months while receiving therapy. Overall, demographic, and disease characteristics of the patients who were not evaluable (not able to maintain clinically inactive disease for the first 6 months) were not significantly different from those of the patients who were evaluable (able to maintain clinically inactive disease for the first 6 months) at study enrollment with the following exceptions ( Table 2) . Males were more likely (P = 0.03) and those who were RF positive were less likely (P = 0.04) to experience clinical remission while receiving medications for the first 6 months. The type of anti-TNF agent received was significantly associated (P = 0.04), with those receiving etanercept being the most likely to experience continuous clinically inactive disease for the first 6 months. Perhaps this is due to etanercept being more likely to be the initial anti-TNF agent used. One (6%) of the 18 patients with extended oligoarticular JIA was unable to maintain clinically inactive disease for 6 months, as were 17 (18%) of the 97 patients who had RF-negative polyarticular JIA and 6 (40%) of the 15 patients who had RF-positive polyarticular JIA (P = 0.04 by Fisher's exact test). Antinuclear antibody status and MTX use were not associated with the ability to maintain clinically inactive disease prior to treatment withdrawal (P = 0.39 and 0.16, respectively, by chi-square test).
Risk of experiencing a flare by 8 months. Sixtyseven (63%) of 106 patients completed the 8-month phase without experiencing a flare. Although the definition of flare did not include either systemic manifestations (related to the systemic form of JIA) or uveitis, these were tracked prospectively at each study visit. No patient demonstrated systemic manifestations, which is not surprising, since patients with systemic JIA were excluded. Three patients demonstrated uveitis flare during the study and, if this occurred during the time after stopping anti-TNF therapy, they were considered to have experienced a flare and removed from the study. The mean/median AE SEM time to flare was 212/250 AE 9.8 days. Table 3 presents the HRs for experiencing a flare based on * HR = hazard ratio; 95% CI = 95% confidence interval; JIA = juvenile idiopathic arthritis; RF = rheumatoid factor; ANA = antinuclear antibody; anti-TNF = anti-tumor necrosis factor. † The analysis included 105 patients.
FLARE OF POLYARTICULAR JIA AFTER STOPPING ANTI-TNF THERAPYdemographic, disease, and treatment characteristics. Older age at disease onset, older age at diagnosis, and shorter disease duration were significantly associated with a lower risk of disease flare. Table 3 shows HRs determined using univariable Cox regression time-to-event analyses and associated significance levels. Five variables were found to be significantly associated with the likelihood of a flare by 8 months. Older age at onset and diagnosis, shorter disease duration at enrollment in the study, and shorter time from disease onset until first occurrence of clinically inactive disease were significant predictors of decreased risk of flare. Longer duration of clinically inactive disease prior to discontinuation of anti-TNF agents was a significant predictor * Values are the number of patients who experienced a flare/effect sample size (mean AE SEM rate of flare). The analysis was divided into 2 intervals (0-4 months and >4-10 months) to accommodate the fact that some patients were seen up to 10 months after stopping anti-tumor necrosis factor (anti-TNF) therapy. JIA = juvenile idiopathic arthritis; RF = rheumatoid factor; ANA = antinuclear antibody; MTX = methotrexate. † The analysis included 103 patients. ‡ The analysis included 104 patients. § The analysis included 105 patients.
of increased risk of flare. Thus, some variables may help to predict the risk of flare based on Cox regression analysis. Supplementary Table 1 (available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.40509/abstract) compares those who either failed to maintain clinically inactive disease in the first 6 months or experienced a flare within the 8 months after discontinuation of anti-TNF therapy to those who were able to both maintain clinically inactive disease in the first 6 months and did not experience a flare within the 8 months after discontinuation of anti-TNF therapy. No variables were significantly different between these 2 groups. Table 4 provides the number of patients who experienced a flare and rate of flare at various study visits for each stratum of independent variables. Because of logistical difficulties in returning children to the clinic for study visits on an exact date, the end-of-study visit occurred after 8 months but prior to or by 10 months of follow-up for 39 patients. Using life-table analyses, significant differences were found in flare rates for age at onset, age at diagnosis, time from disease onset to first occurrence of clinically inactive disease, and time from first occurrence of clinically inactive disease to baseline study visit. However, stepwise logistic regression identified older age at diagnosis (odds ratio [OR] 1.14 [95% confidence interval (95% CI) 1.02- Figure 2A provides a Kaplan-Meier curve showing the probability of flare among all evaluable patients throughout the 8-month phase. As mentioned above, because of logistical difficulties, the end-of-study visit occurred later than 8 months for some patients (up to 10 months). The mean AE SEM time to flare was 7.01 AE 0.32 months with a median of 8.26 months (95% CI 7.80-8.66). Figures 2B-D present survival curves using 3 independent variables that had been hypothesized to predict flare rate and time to flare (whether or not the patient was receiving MTX, the type of anti-TNF agent given prior to discontinuation of therapy, and subtype of JIA). None of these variables proved to be statistically significant predictors of either likelihood of flare or time to flare.
DISCUSSION
In this study, several new and clinically relevant observations were made about stopping anti-TNF therapy in patients with clinically inactive polyarticular forms of JIA. Clinically inactive disease was an unstable state, and 18.5% of the patients were unable to maintain clinically inactive disease for 6 continuous months of observation, even while continuing to receive the anti-TNF agent and stable doses of all background medications. This was especially true for the RF-positive polyarthritis group. Unlike the studies of stopping MTX (in the absence of anti-TNF therapy), the duration of clinically inactive disease at the time of stopping anti-TNF therapy was significantly related to the likelihood of flare. In studies examining the effect of discontinuing MTX, durations of clinically inactive disease of 6, 12, and 18 months all resulted in a similar flare rate of~50% (40, 41) . However, in this study there was an increased risk of disease flare with longer duration of clinically inactive disease. These data certainly do not support the existence of a protective effect of longer duration of clinically inactive disease before considering stopping anti-TNF therapy. In fact, the data suggest that clinically inactive disease, even in those who did demonstrate it consistently for the first 6 months of the study, continued to be an unstable clinical state and prolonged clinically inactive disease resulted in a significantly greater risk of flare.
Our results are consistent with a growing body of literature suggesting that there is a "window of opportunity" early in the treatment of JIA that supports early introduction of aggressive therapy and that rapid achievement of clinically inactive disease will result in better long-term control of JIA and improved outcomes (4, (42) (43) (44) . In a secondary analysis of data from the Trial of Early Aggressive Therapy (TREAT) in JIA (4), the duration of disease prior to initiation of aggressive therapy was significantly inversely associated with the ability to realize clinically inactive disease while receiving aggressive therapy. For each month less of disease duration prior to initiating aggressive therapy, the likelihood of reaching clinically inactive disease was increased 1.7-fold. In this study, longer duration of disease prior to first achieving clinically inactive disease was significantly associated with a decreased ability to maintain clinically inactive disease after stopping the anti-TNF agent.
The major strength of this study is that subjects were followed up prospectively according to protocol and all assessments and determinations of disease status (clinically inactive disease, flare versus no flare) were done with real-time assessment centrally at the study coordinating center. In addition, 137 (93.1%) of the 147 eligible subjects screened were enrolled. However, this study also has limitations. Perhaps the largest shortcoming is that we did not capture the difficulty of regaining clinically inactive disease among those who experienced a flare. This shortcoming will be addressed in a paper describing the longer follow-up of this cohort. The study population was small and not population based. The patients were all recruited from academic pediatric rheumatology centers, which may have introduced a selection bias for patients with more severe disease. If patients with milder disease were enrolled, then perhaps the flare rate would have been lower. The proportion experiencing a flare was smaller than predicted in the preliminary power analysis, further limiting power. The protocol did not specify "study visit windows" outside of which data would be discarded. While >90% of visits occurred within 2 weeks of the expected study date, some were outside this span. These data were used in the analysis. Estimation of the exact time-to-flare is challenging. Flares could only be determined by the examining physician and, therefore, could only occur at study visits. Thus, it is possible that some patients experienced a flare before their study visit. However, unscheduled study visits were performed and actual time of study visit was used in the data analysis for patients who were more symptomatic.
Despite the tremendous potential in JIA for the use of biomarker panels to determine exactly who is the best candidate for a therapy, and which therapy is more likely to induce remission, biomarker studies have yet to produce a validated assay (31) . However, studies of serum levels of S100A8/A9 have demonstrated good-to-excellent ability (sensitivity 100% and specificity 70%) to predict flares in JIA patients stopping MTX (41) . The predictive ability of S100A8/A9 and S100A12 has been evaluated in samples collected in this study and will be described in a future report. Increasingly, ultrasound and magnetic resonance imaging (MRI) are being used to assess JIA patients with clinically inactive disease. However, the few studies of the ability of ultrasound to predict flare in JIA patients with clinically inactive disease have provided conflicting results (45, 46) . The predictive ability of MRI findings in JIA patients with clinically inactive disease has not been assessed.
A central issue in study design was which of several published definitions of flare to use. We considered but eventually chose not to use the definition used by Foell et al (41) , in which worsening in any one of the selected parameters was considered a disease flare. A multifactored definition of flare was selected to provide enough rigor in the degree of worsening to avoid the visit-to-visit minor variation in disease activity and to minimize the effect of the "noise" in the individual assessment measures that is especially influential in low disease activity states. We wanted the flare definition to represent enough worsening that it would likely result in a need for a change in systemic JIA therapy and not just a minor adjustment or injection of 1-2 joints. The definition chosen was also one that had been formally validated in a methodologic paper (33) and field tested in clinical trials (5, 9, 10, 16) .
In conclusion, we offer the following observations that may be informative for the clinical care of children with JIA. In this prospective study of children with polyarticular forms of JIA who achieve clinically inactive disease while receiving anti-TNF therapy recruited from the population of patients routinely seen in pediatric rheumatology centers, clinically inactive disease is an unstable condition in about one-fifth of patients. Following discontinuation of the anti-TNF agent in those who did achieve clinical remission on medications, the mean time to flare was~7.0 months, and by 8 months over a third experienced a flare. The data do not support the effectiveness of continuing background MTX in those who do stop anti-TNF therapy as a method to decrease the risk of flare. Longer duration of clinically inactive disease prior to stopping anti-TNF therapy was associated with an increased risk of flare and thus does not support the perception that longer maintenance of anti-TNF therapy confers decreased risk of flare in those who have already achieved at least 6 months of clinically inactive disease.
